Daily8h
Roche gets USFDA nod for Ocrevus Zunovo for relapsing and progressive multiple sclerosis
Basel: Roche announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO ...
The Pharma Letter10h
Strong new data for Briumvi in MS
TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...
New study uncovers therapeutic inertia in the treatment of women with multiple sclerosis
A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting ...
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...
sciencex1d
$1 Million Grant to Fund Research of Nerve Regeneration in Multiple Sclerosis Patients
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
healthday1d
Some People With MS May Need Earlier, Higher-Dose Meds
Highly effective MS treatments like monoclonal antibodies and immune-suppressing drugs “may lead to better clinical outcomes ...
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
DAYBREAK was a Phase 3, multi-center, long-term open-label extension study to evaluate the safety and efficacy of Zeposia (ozanimod) administered orally to patients with relapsing forms of multiple ...
Early treatment significantly reduces long-term disability in children with multiple sclerosis, new study finds
New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...
The American Journal of Managed Care2d
Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
Pharmabiz2d
US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS
US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS: Basel Tuesday, September 17, 2024, 10:00 Hrs [IST] Roche announced that the United States ...
News Medical2d
Study uncovers ancestry-specific genetic links to multiple sclerosis risk
A landmark study has uncovered novel ancestry-specific genetic variants linked to multiple sclerosis (MS), offering new insights that could reshape treatment approaches for diverse populations ...